Product Information
Cymbalta is safe and tolerable when used as directed, with a once-daily recommended dose of 60 mg for patients with MDD, GAD, DPNP, and fibromyalgia. Cymbalta offered proven efficacy across all 4 of these indications.
Patient Support
Discover resources to help you and your patients. This section offers tools to assist you in assessing, educating, and supporting your patients.
Professional Resources
Ongoing education and development is essential to providing your patients with the best care possible. The interactive learning tools, scientific literature, and news and events featured here are intended to facilitate this education and development.
Learn more about Cymbalta in these indications:
Although the mechanism of antidepressant, anxiolytic, and analgesic actions of Cymbalta in humans is not fully known, it is believed to be related to its potentiation of serotonergic and noradrenergic activity in the central nervous system.
Read the full Prescribing Information
The full Prescribing Information for Cymbalta is now available online for quick and easy cross-referencing, or you can download the PDF version (PDF: 260KB).
Print these tools and resources to give to your patients.
Visit these educational resources, patient screeners, and tools for support online.
Access full studies concerning Cymbalta in the treatment of MDD and GAD.
Listen to experts and peers in podcasts and view Interactive Education about Cymbalta to learn more about Cymbalta for specific indications.
Find insurance providers covering Cymbalta in your state.
Stay current with latest news regarding Cymbalta and Eli Lilly and Company, as well as events across the country.
